• News
  • Publications
  • Videos
  • Events
  • About
  • Contact

TYME Technologies, NYU Langone to Advance Metastatic Cancer Treatment

August 6, 2019

Tyme Technologies, Inc . entered a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer. The broad collaboration will examine the effects of TYME’s cancer metabolism-based therapy, SM-88, and each of the components of MPS (methoxsalen, […]

Click here to view original web page at TYME Technologies, NYU Langone to Advance Metastatic Cancer Treatment

Weekly Digest

Sign up to receive
weekly updates!

    No Spum Guarantee

    Cancer Types

    • Bladder Cancer Research (2)
    • Bowel Cancer Research (3)
    • Brain Cancer Research (7)
    • Breast cancer (6)
    • cervical cancer (1)
    • colon (1)
    • Colon cancer (14)
    • colorectal cancer (6)
    • Drug development (12)
    • Endometrial cancer (2)
    • Esophageal cancer (3)
    • Gastric cancer (5)
    • Hans Clevers (1)
    • Head and neck cancer (4)
    • Immunotherapy (0)
    • Intestinal cancer (8)
    • intestinal organoids (1)
    • Kidney cancer (3)
    • Leukemia (1)
    • Liver cancer (11)
    • Lung cancer (4)
    • melanoma (1)
    • metastatic cancer (1)
    • Organoid (143)
    • Ovarian cancer (8)
    • Pancreatic cancer (19)
    • Peritoneal cancer (1)
    • Personalized medicine (5)
    • Prostate cancer (7)
    • Rectal cancer (1)
    • solid tumor (1)
    • stem cells (1)

    ORG
    1-617-547-9443

    Monday-Friday: 8 am - 8 pm
    Saturday: 8 am - 4:30 pm

    • News
    • Publications
    • Videos
    • Events
    • About Us
    • Contact Us
    • Privacy
    • Terms of Use

    © COPYRIGHT 2023 Organoid Research Group. ALL RIGHTS RESERVED.